This 2 arm study will investigate Quality of Life response in anemic participants with solid and lymphoid malignancies, who are receiving concomitant chemotherapy. Participants with solid and lymphoid malignancies will receive epoetin beta at a dose of 150 international units per kilogram (IU/kg) three times weekly. Participants with lymphoid malignancies will receive epoetin beta 30000 IU once weekly.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percentage of Participants Who Achieved a Clinical Response 3-4 Weeks After Start of Treatment
Timeframe: 3-4 weeks
Percentage of Participants Who Achieved a Clinical Response 6-8 Weeks After Start of Treatment
Timeframe: 6-8 weeks
Percentage of Participants Who Achieved a Clinical Response 10-12 Weeks After Start of Treatment
Timeframe: 10-12 weeks
Percentage of Participants Who Achieved a Clinical Response 3-4 Weeks After Start of Treatment with Mixed Dosing Regimen
Timeframe: 3-4 weeks
Percentage of Participants Who Achieved a Clinical Response 6-8 Weeks After Start of Treatment with Mixed Dosing Regimen
Timeframe: 6-8 weeks
Percentage of Participants Who Achieved a Clinical Response 10-12 Weeks After Start of Treatment with Mixed Dosing Regimen
Timeframe: 10-12 weeks
Quality of Life of Anemic Participants Using Short Form 36 (SF-36) Questionnaire Prior To Treatment
Timeframe: Baseline
Quality of Life of Anemic Participants Using SF-36 Questionnaire 3-4 Weeks After Start of Treatment
Timeframe: 3-4 Weeks
Quality of Life of Anemic Participants Using SF-36 Questionnaire 6-8 Weeks After Start of Treatment
Timeframe: 6-8 Weeks
Quality of Life of Anemic Participants Using SF-36 Questionnaire 10-12 Weeks After Start of Treatment
Timeframe: 10-12 Weeks
Percentage of Participants With Quality of Life Integral Value (IV) Reduction Prior To Treatment
Timeframe: Baseline
Percentage of Participant With Quality of Life IV Reduction 3-4 Weeks After Start of Treatment
Timeframe: 3-4 Weeks
Percentage of Participant With Quality of Life IV Reduction 6-8 Weeks After Start of Treatment
Timeframe: 6-8 Weeks
Percentage of Participant With Quality of Life IV Reduction 10-12 Weeks After Start of Treatment
Timeframe: 10-12 Weeks
Percentage of Participant With Characteristics of The Quality of Life Related Response To Treatment 3-4 Weeks After Start of Treatment
Timeframe: 3-4 Weeks
Percentage of Participant With Characteristics of The Quality of Life Related Response To Treatment 6-8 Weeks After Start of Treatment
Timeframe: 6-8 Weeks
Percentage of Participant With Characteristics of The Quality of Life Related Response To Treatment 10-12 Weeks After Start of Treatment
Timeframe: 10-12 Weeks
Fatigue Severity Score at Baseline
Timeframe: Baseline
Fatigue Severity Score 3-4 Weeks After Start of Treatment
Timeframe: 3-4 Weeks
Fatigue Severity Score 6-8 Weeks After Start of Treatment
Timeframe: 6-8 Weeks
Fatigue Severity Score 10-12 Weeks After Start of Treatment
Timeframe: 10-12 Weeks
Percentage of Participant With Various Fatigue Severity Prior To Treatment
Timeframe: Baseline
Percentage of Participant With Various Fatigue Severity 3-4 Weeks After Start of Treatment
Timeframe: 3-4 Weeks
Percentage of Participant With Various Fatigue Severity 6-8 Weeks After Start of Treatment
Timeframe: 6-8 Weeks
Percentage of Participant With Various Fatigue Severity 10-12 Weeks After Start of Treatment
Timeframe: 10-12 Weeks
Percentage of Participant With Different Symptoms Prior to Treatment (MDASI Questionnaire)
Timeframe: Baseline
Percentage of Participant With Different Symptoms 3-4 Weeks After Start of Treatment (MDASI Questionnaire)
Timeframe: 3-4 Weeks
Percentage of Participant With Different Symptoms 6-8 Weeks After Start of Treatment (MDASI Questionnaire)
Timeframe: 6-8 Weeks
Percentage of Participant With Different Symptoms 10-12 Weeks After Start of Treatment (MDASI Questionnaire)
Timeframe: 10-12 Weeks
Severity Score of Different Symptoms Prior toTreatment (MDASI Questionnaire)
Timeframe: Baseline
Severity Score of Different Symptoms 3-4 Weeks After Start of Treatment (MDASI Questionnaire)
Timeframe: 3-4 weeks
Severity Score of Different Symptoms 6-8 Weeks After Start of Treatment (MDASI Questionnaire)
Timeframe: 6-8 Weeks
Severity Score of Different Symptoms 10-12 Weeks After Start of Treatment (MDASI Questionnaire)
Timeframe: 10-12 Weeks
Percentage of Participants With Improvement in Symptoms Severity 10-12 Weeks After Start of Treatment
Timeframe: 10-12 Weeks
Percentage of Participants With Concomitant Symptoms of Various Severity Prior To Treatment
Timeframe: Baseline
Percentage of Participants With Concomitant Symptoms of Various Severity 3-4 Weeks After Start of Treatment
Timeframe: 3-4 weeks
Percentage of Participants With Concomitant Symptoms of Various Severity 4-6 Weeks After Start of Treatment
Timeframe: 4-6 weeks
Percentage of Participants With Concomitant Symptoms of Various Severity 10-12 Weeks After Start of Treatment
Timeframe: 10-12 Weeks
Quality of Life of Anemic Participants With Clinical Response Using SF-36 Questionnaire Prior To Treatment
Timeframe: Baseline
Quality of Life of Anemic Participants With Clinical Response Using SF-36 Questionnaire 3-4 Weeks After Start of Treatment
Timeframe: 3-4 weeks
Quality of Life of Anemic Participants With Clinical Response Using SF-36 Questionnaire 6-8 Weeks After Start of Treatment
Timeframe: 6-8 weeks
Quality of Life of Anemic Participants With Clinical Response Using SF-36 Questionnaire 10-12 Weeks After Start of Treatment
Timeframe: 10-12 weeks
Percentage of Participants With Different Symptoms Who Had Clinical Response Prior to Treatment
Timeframe: Baseline
Percentage of Participants With Different Symptoms Who Had Clinical Response 3-4 Weeks After Start of Treatment
Timeframe: 3-4 weeks
Percentage of Participants With Different Symptoms Who Had Clinical Response 6-8 Weeks After Start of Treatment
Timeframe: 6-8 weeks
Percentage of Participants With Different Symptoms Who Had Clinical Response 10-12 Weeks After Start of Treatment
Timeframe: 10-12 weeks
Severity Score of Different Symptoms in Anemic Participants With Clinical Response Prior To Treatment
Timeframe: Baseline
Severity Score of Different Symptoms in Anemic Participants With Clinical Response 3-4 Weeks After Start of Treatment
Timeframe: 3-4 weeks
Severity Score of Different Symptoms in Anemic Participants With Clinical Response 6-8 Weeks After Start of Treatment
Timeframe: 6-8 weeks
Severity Score of Different Symptoms in Anemic Participants With Clinical Response 10-12 Weeks After Start of Treatment
Timeframe: 10-12 weeks
Percentage of Participants With Clinical Response After First 3-4 Weeks of Treatment at 30000 IU Once Weekly Dose
Timeframe: 3-4 Weeks
Percentage of Participants With Clinical Response After Second 3-4 Weeks of Treatment at 30000 IU Once Weekly Dose
Timeframe: 6-8 Weeks
Percentage of Participants With Clinical Response After Third 3-4 Weeks of Treatment at 30000 IU Once Weekly Dose
Timeframe: 10-12 Weeks
Quality of Life in Anemic Participants Receiving Treatment at 30000 IU Once Weekly (SF-36 Questionnaire) Prior to Treatment
Timeframe: Baseline
Quality of Life in Anemic Participants Receiving Treatment at 30000 IU Once Weekly (SF-36 Questionnaire) 3-4 Weeks After Start of Treatment
Timeframe: 3-4 weeks
Quality of Life in Anemic Participants Receiving Treatment at 30000 IU Once Weekly (SF-36 Questionnaire) 6-8 Weeks After Start of Treatment
Timeframe: 6-8 Weeks
Quality of Life in Anemic Participants Receiving Treatment at 30000 IU Once Weekly (SF-36 Questionnaire) 10-12 Weeks After Start of Treatment
Timeframe: 10-12 Weeks
Number of Participants With Lymphoproliferative Disorders and Solid Tumors Who Had Quality of Life IV Reduction Prior to Treatment
Timeframe: Baseline
Number of Participants With Lymphoproliferative Disorders and Solid Tumors Who Had Quality of Life IV Reduction 3-4 Weeks After Start of Treatment
Timeframe: 3-4 Weeks
Number of Participants With Lymphoproliferative Disorders and Solid Tumors Who Had Quality of Life IV Reduction 6-8 Weeks After Start of Treatment
Timeframe: 6-8 Weeks
Number of Participants With Lymphoproliferative Disorders and Solid Tumors Who Had Quality of Life IV Reduction 10-12 Weeks After Start of Treatment
Timeframe: 10-12 Weeks
Percentage of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors Prior Receiving Treatment at 30000 IU Once Weekly
Timeframe: Baseline
Percentage of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors 3-4 Weeks After Start of Treatment at 30000 IU Once Weekly
Timeframe: 3-4 weeks
Percentage of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors 6-8 Weeks After Start of Treatment at 30000 IU Once Weekly
Timeframe: 6-8 weeks
Percentage of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors 10-12 Weeks After Start of Treatment at 30000 IU Once Weekly
Timeframe: 10-12 Weeks
Severity Score of Different Symptoms in Participants With Lymphoproliferative Disorders and Solid Tumors Prior to Treatment at 30000 IU Once Weekly
Timeframe: Baseline
Severity Score of Different Symptoms in Participants With Lymphoproliferative Disorders and Solid Tumors 3-4 Weeks After Start of Treatment at 30000 IU Once Weekly
Timeframe: 3-4 weeks
Severity Score of Different Symptoms in Participants With Lymphoproliferative Disorders and Solid Tumors 6-8 Weeks After Start of Treatment at 30000 IU Once Weekly
Timeframe: 6-8 weeks
Severity Score of Different Symptoms in Participants With Lymphoproliferative Disorders and Solid Tumors 10-12 Weeks After Start of Treatment at 30000 IU Once Weekly
Timeframe: 10-12 weeks
Percentage of Participants With Improvement in Symptoms Severity Categorized by Lymphoproliferative Disorders and Solid Tumors 10-12 Weeks After Start of Treatment
Timeframe: 10-12 Weeks
Number of Participants Who Achieved a Clinical Response 3-4 Weeks After Start of Treatment
Timeframe: 3-4 weeks
Number of Participants Who Achieved a Clinical Response 6-8 Weeks After Start of Treatment
Timeframe: 6-8 weeks
Number of Participants Who Achieved a Clinical Response 10-12 Weeks After Start of Treatment
Timeframe: 10-12 weeks
Number of Participants Who Achieved a Clinical Response With Mixed Drug Dosing Regimen, 3-4 Weeks After Start of Treatment
Timeframe: 3-4 weeks
Number of Participants Who Achieved a Clinical Response With Mixed Drug Dosing Regimen, 6-8 Weeks After Start of Treatment
Timeframe: 6-8 weeks
Number of Participants Who Achieved a Clinical Response With Mixed Dosing Regimen, 10-12 Weeks After Start of Treatment
Timeframe: 10-12 weeks
Number of Participants With Quality of Life IV Reduction 3-4 Weeks After Start of Treatment
Timeframe: 3-4 Weeks
Number of Participants With Quality of Life IV Reduction 6-8 Weeks After Start of Treatment
Timeframe: 6-8 Weeks
Number of Participants With Quality of Life IV Reduction 10-12 Weeks After Start of Treatment
Timeframe: 10-12 Weeks
Number of Participants With Characteristics of the Quality of Life Related Response To Treatment 3-4 Weeks After Start of Treatment
Timeframe: 3-4 Weeks
Number of Participants With Characteristics of the Quality of Life Related Response To Treatment 6-8 Weeks After Start of Treatment
Timeframe: 6-8 Weeks
Number of Participants With Characteristics of the Quality of Life Related Response To Treatment 10-12 Weeks After Start of Treatment
Timeframe: 10-12 Weeks
Percentage of Participants With Various Fatigue Severity 3-4 Weeks After Start of Treatment
Timeframe: 3-4 Weeks
Percentage of Participants With Various Fatigue Severity 6-8 Weeks After Start of Treatment
Timeframe: 6-8 Weeks
Percentage of Participants With Various Fatigue Severity 10-12 Weeks After Start of Treatment
Timeframe: 10-12 Weeks
Number of Participants With Different Symptoms 3-4 Weeks After Start of Treatment (MDASI Questionnaire)
Timeframe: 3-4 Weeks
Number of Participant With Different Symptoms 6-8 Weeks After Start of Treatment (MDASI Questionnaire)
Timeframe: 6-8 Weeks
Number of Participants With Different Symptoms 10-12 Weeks After Start of Treatment (MDASI Questionnaire)
Timeframe: 10-12 Weeks
Number of Participants With Improvement in Symptoms Severity 10-12 Weeks After Start of Treatment
Timeframe: 10-12 Weeks
Number of Participants With Concomitant Symptoms of Various Severity 3-4 Weeks After Start of Treatment
Timeframe: 3-4 weeks
Number of Participants With Concomitant Symptoms of Various Severity 6-8 Weeks After Start of Treatment
Timeframe: 6-8 weeks
Number of Participants With Concomitant Symptoms of Various Severity 10-12 Weeks After Start of Treatment
Timeframe: 10-12 Weeks
Number of Participants With Different Symptoms Who Had Clinical Response 3-4 Weeks After Start of Treatment
Timeframe: 3-4 weeks
Number of Participants With Different Symptoms Who Had Clinical Response 6-8 Weeks After Start of Treatment
Timeframe: 6-8 weeks
Number of Participants With Different Symptoms Who Had Clinical Response 10-12 Weeks After Start of Treatment
Timeframe: 10-12 weeks
Number of Participants With Clinical Response After First 3-4 Weeks of Treatment at 30000 IU Once Weekly Dose
Timeframe: 3-4 Weeks
Number of Participants With Clinical Response After Second 3-4 Weeks of Treatment at 30000 IU Once Weekly Dose
Timeframe: 6-8 Weeks
Number of Participants With Clinical Response After Third 3-4 Weeks of Treatment at 30000 IU Once Weekly Dose
Timeframe: 9-12 Weeks
Number of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors Before Receiving Treatment at 30000 IU Once Weekly
Timeframe: Baseline
Number of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors 3-4 Weeks After Start of Treatment at 30000 IU Once Weekly
Timeframe: 3-4 weeks
Number of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors 6-8 Weeks After Start of Treatment at 30000 IU Once Weekly
Timeframe: 6-8 weeks
Number of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors 10-12 Weeks After Start of Treatment at 30000 IU Once Weekly
Timeframe: 10-12 Weeks
Number of Participants With Improvement in Symptoms Severity Categorized by Lymphoproliferative Disorders and Solid Tumors 10-12 Weeks After Start of Treatment at 30000 IU Once Weekly
Timeframe: 10-12 Weeks